Our Team
Our leadership team is composed of scientific and strategic professionals at the forefront of CNS research & development and commercialization, and is strengthened further by leaders in psychology, psychiatry, psychedelics, and oncology.
Management
Jan-Anders Karlsson, PhD
Interim CEO, Founder, Board Member
Anne C. Andorn, MD
Chief Medical Officer
Satish Prabhu, CPA
Chief Financial Officer
Åsa Holmgren, MSc Pharm
Head of Regulatory Affairs
Susan Learned, MD, PharmD, PhD
Head of Research & Development
Wilhelm Stahl, PhD
Head of CMC
Board of Directors
Philip Taub
Founder, Board Chair
Jan-Anders Karlsson, PhD
Interim CEO, Founder, Board Member
Lisa Deschamps
Board Member
Greg Hersly
Board Member
Robert Velarde
Board Member
Scientific Advisory Board
Gil Block, MD, PhD
William Breitbart, MD
Jim Grigsby, PhD
David Hellerstein, MD
Benjamin Kelmendi, MD
Strategic Advisory Board
John Andreadis
Mark Corrigan, MD
Stephen Juelsgaard, DVM, JD
Brad Sitko
Richard A. Yacenda
Reset Pharma has acquired an exclusive worldwide license from NYU Langone Health for intellectual property associated with the use of psilocybin and related psychedelics for the treatment of mental illness in patients with life-threatening diseases.
This agreement is based on the seminal work of Stephen Ross, MD, a world leader in advancing research on psychedelic medicine and a prominent psychiatrist with psycho-oncology expertise.
Reset Pharma is addressing demoralization syndrome in patients suffering from cancer
Sign up for our mailing list to learn more about our latest updates